Sienna Biopharmaceuticals, a clinical-stage biopharmaceutical company, has seen promising biopsy data in its most recent clinical trial of a topical solution for psoriasis, according to a statement from the company on Tuesday.
The Westlake Village business tested a non-steroidal topical solution, commonly referred to as SNA-120, on 22 people at Rockefeller University in New York City.
During testing, physicians noted a decrease in epidermal inflammation and a “statistically significant” reduction in T-cell and dendritic cell counts, confirming the immune system’s response to the treatment, Sienna said.
“The clear and substantial impact by Sienna’s SNA-120 on immune cells and the vast array of important psoriasis-related pathways after 12 weeks of treatment is impressive and encouraging for a topical, non-steroidal treatment,” said James Krueger, senior attending physician at the Laboratory for Investigative Dermatology at the University.
Sienna will seek patients for its Phase 3 testing of SNA-120 in the second half of this year, following a positive meeting with the FDA.
Shares of Sienna Biopharmaceuticals (SNNA) closed Tuesday down 11 cents, or 7.7 percent, to $1.32 on the Nasdaq.